GlassScriptPhysician profile
Scott Drayton Worswick
NPI 1871733329
$72,029.71
in general payments reported to CMS, 2019-2025
17 companies · $3,344 in 2025
The $3,344 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.61 · 2020: $16.33 · 2021: $397 · 2022: $1,738 · 2023: $40K · 2024: $27K · 2025: $3,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $16K · Food and Beverage: $3,688 · Travel and Lodging: $3,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,200.00 |
| Consulting Fee | $15,655.25 |
| Food and Beverage | $3,688.01 |
| Travel and Lodging | $3,298.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $68,986.84 | 2021-2025 | Spevigo |
| Ucb, INC. | $722.71 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $628.30 | 2022-2025 | Sotyktu |
| Abbvie INC. | $475.38 | 2019-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $347.87 | 2021-2025 | |
| Dermavant Sciences, INC. | $147.74 | 2023 | Vtama |
| Springworks Therapeutics, INC. | $134.76 | 2025 | Gomekli |
| Genzyme Corporation | $120.17 | 2025 | |
| Sanofi-Aventis U.S. LLC | $111.59 | 2021 | |
| Pfizer INC. | $81.31 | 2023 | |
| Cipher Pharmaceuticals US LLC | $68.83 | 2025 | Natroba, Spinosad |
| Lilly USA, LLC | $54.52 | 2024 | Taltz, Olumiant, Zepbound |
| Regeneron Pharmaceuticals, INC. | $53.80 | 2021-2023 | Dupixent |
| Amgen INC. | $31.63 | 2023-2024 | Otezla |
| Janssen Biotech, INC. | $30.88 | 2024 | Tremfya |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $17.05 | 2019 | |
| Smith+Nephew, INC. | $16.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Worswick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.